Abstract: The present invention relates to deletion and substitution mutant polypeptides of human chemokine ?-7 (Ck?-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck?-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck?-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Abstract: The present invention provides a Stem Cell Inhibitor (SCI) protein which comprises at least one amino acid alteration from its native form which protein does not significantly aggregate but which retains substantially unaltered stem cell inhibitory activity. The alteration is preferably a conservative subsitution of a charged amino acid residue. Such proteins may be used in treating stem cells in a patient undergoing chemotherapy.

Abstract: The present invention provides a Stem Cell Inhibitor (SCI) protein which comprises at least one amino acid alteration from its native form which protein does not significantly aggregate but which retains substantially unaltered stem cell inhibitory activity. The alteration is preferably a conservative subsitution of a charged amino acid residue. Such proteins may be used in treating stem cells in a patient undergoing chemotherapy.

Abstract: The present invention provides a Stem Cell Inhibitor (SCT) protein which comprises at least one amino acid alteration from its active form which protein does not significantly aggregate but which retains substantially unaltered stem cell inhibitory activity. The alteration is preferably a conservative substitution of a charged amino acid residue. Such proteins may be used in treating stem cells in a patient undergoing chemotherapy.